Browsing Tag
Antengene Corporation Limited
3 posts
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
Antengene deepens oncology ambitions with three next-generation ADC and T-cell engager programs at AACR 2026
Discover how Antengene Corporation Limited’s AACR 2026 oncology presentations could reshape its pipeline strategy and investor outlook. Read the full analysis.
Antengene–UCB autoimmune deal: Why the $1.1bn ATG-201 partnership could reshape B-cell targeting therapies
Antengene licenses ATG-201 to UCB in a $1.1B autoimmune drug deal. Discover why bispecific antibodies are becoming the next frontier in immunology.